548 Episodio

  1. Deriving Rare Disease Therapies from Human Plasma

    Pubblicato: 18/10/2017
  2. Learning to Live with Purpose

    Pubblicato: 11/10/2017
  3. A Mother's Race to Find a Treatment for Her Daughter's Ultra-Rare Condition

    Pubblicato: 04/10/2017
  4. Screening for Rare Diseases

    Pubblicato: 27/09/2017
  5. A Look at the Changing World of Work for People with a Chronic Illness

    Pubblicato: 20/09/2017
  6. Aligning Interests in Rare Disease Partnerships

    Pubblicato: 13/09/2017
  7. A Veteran Venture Capitalist Discusses Investing in Rare Disease Drug Development

    Pubblicato: 06/09/2017
  8. A Patient Group Crafts Guidelines for Working with Pharma

    Pubblicato: 30/08/2017
  9. Bringing Innovation to Business Models for Rare Disease Drug Development

    Pubblicato: 23/08/2017
  10. Rethinking Accessibility and Dependency

    Pubblicato: 16/08/2017
  11. How Simon Wheatcroft, Blinded by a Rare Disease, Became an Ultramarathoner

    Pubblicato: 09/08/2017
  12. Spark Hoping Its Luxturna Will Become First FDA-Approved Gene Therapy

    Pubblicato: 02/08/2017
  13. What Rare Patient-Investors Can Learn From Venture Capitalists

    Pubblicato: 26/07/2017
  14. Novel Effort Delivers Failed DMD Drug to Former Clinical Trial Participants

    Pubblicato: 19/07/2017
  15. Centogene Seeks to Deliver Diagnoses to Rare Disease Patients Early

    Pubblicato: 12/07/2017
  16. Albireo Advances Pipeline for Rare Liver and Gastrointestinal Diseases

    Pubblicato: 05/07/2017
  17. aTyr Pharma Seeks to Modulate Activity in FSHD and Other Rare Disease

    Pubblicato: 28/06/2017
  18. Summit Pursues A Different Approach to Treating Duchenne

    Pubblicato: 21/06/2017
  19. Delivering Enzyme Replacement Therapies Across the Blood-Brain Barrier

    Pubblicato: 14/06/2017
  20. Sangamo Advances Gene Editing Therapies for Multiple Rare Diseases into the Clinic

    Pubblicato: 07/06/2017

21 / 28

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Visit the podcast's native language site